S3-Leitlinie Diagnostik und Therapie biliärer Karzinome

Michael Bitzer; Sabrina Groß; Jörg Albert; Judit Boda-Heggemann; Thomas Brunner; Reiner Caspari; Enrico De Toni; Frank Dombrowski; Matthias Evert; Andreas Geier; Eleni Gkika; Martin Götz; Thomas Helmberger; Ralf-Thorsten Hoffmann; Peter Huppert; Achim Kautz; David Krug; Christian La Fougère; Hauke Lang; Philipp Lenz; Tom Lüdde; Andreas Mahnken; Silvio Nadalin; Hoa Huu Phuc Nguyen; Johann Ockenga; Karl Oldhafer; Philipp Paprottka; Philippe Pereira; Thorsten Persigehl; Ruben Plentz; Jürgen Pohl; Heinrich Recken; Peter Reimer; Jutta Riemer; Ulrike Ritterbusch; Elke Roeb; Jörn Rüssel; Barbara Schellhaas; Peter Schirmacher; Hans Jürgen Schlitt; Irene Schmid; Andreas Schuler; Daniel Seehofer; Marianne Sinn; Andreas Stengel; Christoph Stoll; Andrea Tannapfel; Anne Taubert; Reina Tholen; Jörg Trojan; Ingo van Thiel; Arndt Vogel; Thomas Vogl; Frank Wacker; Oliver Waidmann; Heiner Wedemeyer; Henning Wege; Dane Wildner; Marcus-Alexander Wörns; Peter Galle; Nisar Malek

doi:10.1055/a-2026-1277

Zeitschrift für Gastroenterologie, Inhaltsverzeichnis

Z Gastroenterol 2023; 61(04): 420-440
DOI: 10.1055/a-2026-1277

Leitlinie

S3-Leitlinie Diagnostik und Therapie biliärer Karzinome

Kurzversion

Michael Bitzer

¹Abteilung für Gastroenterologie, Gastrointestinale Onkologie, Hepatologie, Infektiologie und Geriatrie, Eberhard-Karls Universität, Tübingen

,

Sabrina Groß

¹Abteilung für Gastroenterologie, Gastrointestinale Onkologie, Hepatologie, Infektiologie und Geriatrie, Eberhard-Karls Universität, Tübingen

,

Jörg Albert

²Katharinenhospital, Klinik für Allgemeine Innere Medizin, Gastroenterologie, Hepatologie, Infektiologie und Pneumologie, Stuttgart

,

Judit Boda-Heggemann

³Klinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Mannheim

,

Thomas Brunner

⁴Universitätsklinik für Strahlentherapie-Radioonkologie, Medizinische Universität Graz

,

Reiner Caspari

⁵Klinik Niederrhein Erkrankungen des Stoffwechsels der Verdauungsorgane und Tumorerkrankungen, Bad Neuenahr-Ahrweiler

,

Enrico De Toni

⁶Medizinische Klinik und Poliklinik II, LMU München

,

Frank Dombrowski

⁷Institut für Pathologie, Universität Greifswald

,

Matthias Evert

⁸Institut für Pathologie, Universität Regensburg

,

Andreas Geier

⁹Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg

,

Eleni Gkika

¹⁰Klinik für Strahlenheilkunde, Department für Radiologische Diagnostik und Therapie, Universitätsklinikum Freiburg

,

Martin Götz

¹¹Medizinische Klinik IV – Gastroenterologie/Onkologie, Klinikverbund Südwest, Böblingen

,

Thomas Helmberger

¹²Institut für Radiologie, Neuroradiologie und minimal invasive Therapie, München Klinik Bogenhausen

,

Ralf-Thorsten Hoffmann

¹³Institut und Poliklinik für Diagnostische und Interventionelle Radiologie, Universitätsklinikum Dresden

,

Peter Huppert

¹⁴Radiologisches Zentrum, Max Grundig Klinik, Bühlerhöhe

,

Achim Kautz

¹⁵Deutsche Leberhilfe e. V.

,

David Krug

¹⁶Strahlentherapie Campus Kiel, Universitätsklinikum Schleswig-Holstein

,

Christian La Fougère

¹⁷Nuklearmedizin und Klinische Molekulare Bildgebung, Eberhard-Karls Universität, Tübingen

,

Hauke Lang

¹⁸Klinik für Allgemein-, Viszeral- und Transplantationschirurgie, Johannes Gutenberg-Universität, Mainz

,

Philipp Lenz

¹⁹Zentrale Einrichtung Palliativmedizin, Universitätsklinikum Münster

,

Tom Lüdde

²⁰Medizinische Klinik für Gastroenterologie, Hepatologie und Infektiologie, Universitätsklinikum Düsseldorf

,

Andreas Mahnken

²¹Klinik für Diagnostische und Interventionelle Radiologie, Universitätsklinikum Marburg

,

Silvio Nadalin

²²Klinik für Allgemein-, Viszeral- und Transplantationschrirugie, Eberhard-Karls Universität, Tübingen

,

Hoa Huu Phuc Nguyen

²³Institut für Humangenetik, Ruhr-Universität, Bochum

,

Johann Ockenga

²⁴Medizinische Klinik II, Gesundheit Nord, Klinikverbund Bremen

,

Karl Oldhafer

²⁵Klinik für Leber-, Gallenwegs- und Pankreaschirurgie, Asklepios Klinik Barmbek

,

Philipp Paprottka

²⁶Sektion für Interventionelle Radiologie, Klinikum rechts der Isar, Technische Universität München

,

Philippe Pereira

²⁷Zentrum für Radiologie, Minimal-invasive Therapien und Nuklearmedizin, SLK-Klinken Heilbronn

,

Thorsten Persigehl

²⁸Institut für Diagnostische und Interventionelle Radiologie, Universitätsklinikum Köln

,

Ruben Plentz

²⁹Klinik für Innere Medizin, Gesundheit Nord, Klinikverbund Bremen

,

Jürgen Pohl

³⁰Abteilung für Gastroenterologie, Asklepios Klinik Altona

,

Heinrich Recken

³¹Hamburger Fern-Hochschule

,

Peter Reimer

³²Institut für Diagnostische und Interventionelle Radiologie, Städtisches Klinikum Karlsruhe

,

Jutta Riemer

³³Lebertransplantierte e. V.

,

Ulrike Ritterbusch

³⁴Hospizarbeit am Universitätsklinikum Essen

,

Elke Roeb

³⁵Medizinische Klinik II Pneumologie, Nephrologie und Gastroenterologie, Universitätsklinikum Gießen

,

Jörn Rüssel

³⁶Medizinische Klinik IV Hämatologie und Onkologie, Universitätsklinikum Halle (Saale)

,

Barbara Schellhaas

³⁷Medizinische Klinik I Gastroenterologie, Pneumologie und Endokrinologie, Friedrich-Alexander-Universität, Erlangen

,

Peter Schirmacher

³⁸Allgemeine Pathologie und pathologische Anatomie, Universitätsklinikum Heidelberg

,

Hans Jürgen Schlitt

³⁹Klinik und Poliklinik für Chirurgie, Universitätsklinikum Regensburg

,

Irene Schmid

⁴⁰Kinderklinik und Kinderpoliklinik im Dr. von Haunerschen Kinderspital, LMU München

,

Andreas Schuler

⁴¹Medizinische Klinik, Gastroenterologie, Alb-Fils-Kliniken, Geislingen an der Steige

,

Daniel Seehofer

⁴²Klinik und Poliklinik für Viszeral-, Transplantations-, Thorax- und Gefäßchirurgie, Universitätsklinikum Leipzig

,

Marianne Sinn

⁴³II. Medizinische Klinik und Poliklinik (Onkologie, Hämatologie, Knochenmarktransplantation mit Abteilung für Pneumologie), Universitätsklinikum Hamburg-Eppendorf

,

Andreas Stengel

⁴⁴Innere Medizin VI – Psychosomatische Medizin und Psychotherapie, Eberhard-Karls Universität, Tübingen

,

Christoph Stoll

⁴⁵Klinik Herzoghöhe Bayreuth

,

Andrea Tannapfel

⁴⁶Institut für Pathologie, Ruhr-Universität Bochum

,

Anne Taubert

⁴⁷Klinische Sozialarbeit, Universitätsklinikum Heidelberg

,

Reina Tholen

⁴⁸Deutscher Bundesverband für Physiotherapie (ZVK) e. V.

,

Jörg Trojan

⁴⁹Medizinische Klinik 1: Gastroenterologie und Hepatologie, Pneumologie und Allergologie, Endokrinologie und Diabetologie sowie Ernährungsmedizin, Goethe-Universität, Frankfurt

,

Ingo van Thiel

¹⁵Deutsche Leberhilfe e. V.

,

Arndt Vogel

⁵⁰Klinik für Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover

,

Thomas Vogl

⁵¹Institut für Diagnostische und Interventionelle Radiologie, Goethe-Universität, Frankfurt

,

Frank Wacker

⁵²Institut für Diagnostische und Interventionelle Radiologie, Medizinische Hochschule Hannover

,

Oliver Waidmann

⁵³Onkologie Bethanien, Frankfurt am Main

,

Heiner Wedemeyer

⁵⁰Klinik für Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover

,

Henning Wege

⁵⁴Klinik für Allgemeine Innere Medizin, Onkologie/Hämatologie, Gastroenterologie und Infektiologie, Klinikum Esslingen

,

Dane Wildner

⁵⁵Innere Medizin, Krankenhäuser Nürnberger Land GmbH, Standort Lauf

,

Marcus-Alexander Wörns

⁵⁶Klinik für Gastroenterologie, Hämatologie und internistische Onkologie und Endokrinologie, Klinikum Dortmund

,

Peter Galle

⁵⁷1. Medizinische Klinik und Poliklinik, Gastroenterologie, Hepatologie, Nephrologie, Rheumatologie, Infektiologie, Johannes Gutenberg-Universität, Mainz

,

Nisar Malek

¹Abteilung für Gastroenterologie, Gastrointestinale Onkologie, Hepatologie, Infektiologie und Geriatrie, Eberhard-Karls Universität, Tübingen

› Institutsangaben

Abstract

Schlüsselwörter

biliäre Karzinome - hepatobiliäre Karzinome - Cholangiokarzinome - CCA - Diagnostik - Therapie - Risikofaktoren - Gallenblasenkarzinom - Gallengangskarzinom - cholangiozelluläres Karzinom

Volltext

Referenzen

Literatur
1 Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53 (03) 1020-1022 https://pubmed.ncbi.nlm.nih.gov/21374666/
2 Brouwer WP, van der Meer AJP, Boonstra A. et al. Prediction of long-term clinical outcome in a diverse chronic hepatitis B population: Role of the PAGE-B score. J Viral Hepat 2017; 24 (11) 1023-1031 https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jvh.12727?download=true
3 Papatheodoridis G, Dalekos G, Sypsa V. et al. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. J Hepatol 2016; 64 (04) 800-806 https://www.sciencedirect.com/science/article/pii/S0168827815007953?via%3Dihub
4 Inoue M, Yoshimi I, Sobue T. et al. Influence of coffee drinking on subsequent risk of hepatocellular carcinoma: a prospective study in Japan. J Natl Cancer Inst 2005; 97 (04) 293-300 https://pubmed.ncbi.nlm.nih.gov/15713964/
5 Bravi F, Tavani A, Bosetti C. et al. Coffee and the risk of hepatocellular carcinoma and chronic liver disease: a systematic review and meta-analysis of prospective studies. Eur J Cancer Prev 2017; 26 (05) 368-377
6 Aleksandrova K, Bamia C, Drogan D. et al. The association of coffee intake with liver cancer risk is mediated by biomarkers of inflammation and hepatocellular injury: data from the European Prospective Investigation into Cancer and Nutrition. Am J Clin Nutr 2015; 102 (06) 1498-1508 http://spiral.imperial.ac.uk/bitstream/10044/1/29882/11/Am%20J%20Clin%20Nutr-2015-Aleksandrova-1498-508.pdf
7 Setiawan VW, Wilkens LR, Lu SC. et al. Association of coffee intake with reduced incidence of liver cancer and death from chronic liver disease in the US multiethnic cohort. Gastroenterology 2015; 148 (01) 118-125 https://ac.els-cdn.com/S0016508514012001/1-s2.0-S0016508514012001-main.pdf?_tid=19814e3e-2d8a-41ee-8c4e-496c2d8bda0a&acdnat=1553011004_92a7790325afb3e4f2cc4820eb51895a
8 Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004; 130 (07) 417-422 https://link.springer.com/content/pdf/10.1007%2Fs00432-004-0552-0.pdf
9 Pocha C, Dieperink E, McMaken KA. et al. Surveillance for hepatocellular cancer with ultrasonography vs. computed tomography – a randomised study. Aliment Pharmacol Ther 2013; 38 (03) 303-312 https://onlinelibrary.wiley.com/doi/pdf/10.1111/apt.12370
10 Trinchet JC, Chaffaut C, Bourcier V. et al. Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities. Hepatology 2011; 54 (06) 1987-1997 https://aasldpubs.onlinelibrary.wiley.com/doi/pdf/10.1002/hep.24545
11 Tzartzeva K, Obi J, Rich NE. et al. Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis. Gastroenterology 2018; 154 (06) 1706-1718.e1 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5927818/pdf/nihms940431.pdf
12 Ioannou GN, Beste LA, Green PK. et al. Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores. Gastroenterology 2019; 157 (05) 1264-1278.e4 https://www.sciencedirect.com/science/article/abs/pii/S001650851941130X?via%3Dihub
13 Song BG, Sinn DH, Chi S. et al. Additional role of liver stiffness measurement in stratifying residual hepatocellular carcinoma risk predicted by serum biomarkers in chronic hepatitis B patients under antiviral therapy. Eur J Gastroenterol Hepatol 2018; 30 (12) 1447-1452
14 Kanwal F, Kramer JR, Asch SM. et al. Long-Term Risk of Hepatocellular Carcinoma in HCV Patients Treated With Direct Acting Antiviral Agents. Hepatology 2020; 71 (01) 44-55 https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hep.30823?download=true
15 Raffetti E, Fattovich G, Donato F. Incidence of hepatocellular carcinoma in untreated subjects with chronic hepatitis B: a systematic review and meta-analysis. Liver Int 2016; 36 (09) 1239-1251 https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/liv.13142?download=true
16 Papatheodoridis GV, Chan HL, Hansen BE. et al. Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy. J Hepatol 2015; 62 (04) 956-967 https://air.unimi.it/retrieve/handle/2434/437611/717191/1-s2.0-S0168827815000045-main.pdf
17 Kanwal F, Kramer JR, Mapakshi S. et al. Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease. Gastroenterology 2018; 155 (06) 1828-1837.e2 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6279617/pdf/nihms-1504451.pdf
18 Simeone JC, Bae JP, Hoogwerf BJ. et al. Clinical course of nonalcoholic fatty liver disease: an assessment of severity, progression, and outcomes. Clin Epidemiol 2017; 9: 679-688 https://www.dovepress.com/front_end/cr_data/cache/pdf/download_1607712668_5fd3bf9ca7fc4/CLEP-144368-natural-history-of-non-alcoholic-fatty-liver-disease-----non_121317.pdf
19 Haradome H, Grazioli L, Tinti R. et al. Additional value of gadoxetic acid-DTPA-enhanced hepatobiliary phase MR imaging in the diagnosis of early-stage hepatocellular carcinoma: comparison with dynamic triple-phase multidetector CT imaging. J Magn Reson Imaging 2011; 34 (01) 69-78 https://onlinelibrary.wiley.com/doi/pdf/10.1002/jmri.22588
20 Burrel M, Llovet JM, Ayuso C. et al. MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology 2003; 38 (04) 1034-1042 https://aasldpubs.onlinelibrary.wiley.com/doi/pdf/10.1002/hep.1840380430
21 Di Martino M, De Filippis G, De Santis A. et al. Hepatocellular carcinoma in cirrhotic patients: prospective comparison of US, CT and MR imaging. Eur Radiol 2013; 23 (04) 887-896 https://link.springer.com/content/pdf/10.1007%2Fs00330-012-2691-z.pdf
22 Khalili K, Kim TK, Jang HJ. et al. Optimization of imaging diagnosis of 1-2 cm hepatocellular carcinoma: an analysis of diagnostic performance and resource utilization. J Hepatol 2011; 54 (04) 723-728 https://www.sciencedirect.com/science/article/pii/S0168827810008147?via%3Dihub
23 Chan AC, Fan ST, Poon RT. et al. Evaluation of the seventh edition of the American Joint Committee on Cancer tumour-node-metastasis (TNM) staging system for patients undergoing curative resection of hepatocellular carcinoma: implications for the development of a refined staging system. HPB (Oxford) 2013; 15 (06) 439-448 https://www.hpbonline.org/article/S1365-182X(15)31417-9/pdf
24 Chevret S, Trinchet JC, Mathieu D. et al. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. J Hepatol 1999; 31 (01) 133-141 https://www.journal-of-hepatology.eu/article/S0168-8278(99)80173-1/fulltext
25 Johnson PJ, Berhane S, Kagebayashi C. et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol 2015; 33 (06) 550-558 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4322258/pdf/zlj550.pdf
26 Kitai S, Kudo M, Minami Y. et al. Validation of a new prognostic staging system for hepatocellular carcinoma: a comparison of the biomarker-combined Japan Integrated Staging Score, the conventional Japan Integrated Staging Score and the BALAD Score. Oncology 2008; 75 (Suppl. 01) 83-90 https://www.karger.com/Article/Abstract/173428
27 Leung TW, Tang AM, Zee B. et al. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer 2002; 94 (06) 1760-1769 https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.10384
28 Marrero JA, Fontana RJ, Barrat A. et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 2005; 41 (04) 707-716 https://pubmed.ncbi.nlm.nih.gov/15795889/
29 Pinato DJ, Sharma R, Allara E. et al. The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma. J Hepatol 2017; 66 (02) 338-346 https://www.journal-of-hepatology.eu/article/S0168-8278(16)30535-9/pdf
30 Vitale A, Saracino E, Boccagni P. et al. Validation of the BCLC prognostic system in surgical hepatocellular cancer patients. Transplant Proc 2009; 41 (04) 1260-1263 https://www.sciencedirect.com/science/article/pii/S0041134509004850?via%3Dihub
31 Yau T, Tang VY, Yao TJ. et al. Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology 2014; 146 (07) 1691-1700.e3 https://www.gastrojournal.org/article/S0016-5085(14)00243-1/pdf
32 EASL Clinical Practice Guidelines. Management of hepatocellular carcinoma. J Hepatol 2018; 69 (01) 182-236 https://www.sciencedirect.com/science/article/pii/S0168827818302150
33 Huang X, Lu S. Impact of preoperative locoregional therapy on recurrence and patient survival following liver transplantation for hepatocellular carcinoma: a meta-analysis. Scand J Gastroenterol 2017; 52 (02) 143-149 https://www.tandfonline.com/doi/full/10.1080/00365521.2016.1236396
34 Kulik L, Heimbach JK, Zaiem F. et al. Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: A systematic review and meta-analysis. Hepatology 2018; 67 (01) 381-400 https://aasldpubs.onlinelibrary.wiley.com/doi/full/10.1002/hep.29485
35 Sneiders D, Houwen T, Pengel LHM. et al. Systematic Review and Meta-Analysis of Posttransplant Hepatic Artery and Biliary Complications in Patients Treated With Transarterial Chemoembolization Before Liver Transplantation. Transplantation 2018; 102 (01) 88-96
36 Degroote H, Callebout E, Iesari S. et al. Extended criteria for liver transplantation in hepatocellular carcinoma. A retrospective, multicentric validation study in Belgium. Surg Oncol 2020; 33: 231-238 https://pubmed.ncbi.nlm.nih.gov/31630912/
37 Parikh ND, Waljee AK, Singal AG. Downstaging hepatocellular carcinoma: A systematic review and pooled analysis. Liver Transpl 2015; 21 (09) 1142-1152 https://deepblue.lib.umich.edu/bitstream/handle/2027.42/113108/lt24169.pdf?sequence=1
38 Bruix J, Takayama T, Mazzaferro V. et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol 2015; 16 (13) 1344-1354 https://www.sciencedirect.com/science/article/pii/S1470204515001989?via%3Dihub
39 Lee JH, Lee JH, Lim YS. et al. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. Gastroenterology 2015; 148 (07) 1383-1391.e6 https://www.sciencedirect.com/science/article/pii/S0016508515003054?via%3Dihub
40 Mazzaferro V, Romito R, Schiavo M. et al. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 2006; 44 (06) 1543-1554 https://aasldpubs.onlinelibrary.wiley.com/doi/pdf/10.1002/hep.21415
41 Samuel M, Chow PK, Chan Shih-YenE. et al. Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma. Cochrane Database Syst Rev 2009; (01) Cd001199
42 Takayama T, Sekine T, Makuuchi M. et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 2000; 356: 802-807 https://www.sciencedirect.com/science/article/pii/S0140673600026544?via%3Dihub
43 Chen MS, Li JQ, Zheng Y. et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 2006; 243 (03) 321-328 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1448947/pdf/20060300s00006p321.pdf
44 Feng K, Yan J, Li X. et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. J Hepatol 2012; 57 (04) 794-802 https://www.sciencedirect.com/science/article/pii/S0168827812003613?via%3Dihub
45 Huang J, Yan L, Cheng Z. et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg 2010; 252 (06) 903-912
46 Ng KKC, Chok KSH, Chan ACY. et al. Randomized clinical trial of hepatic resection versus radiofrequency ablation for early-stage hepatocellular carcinoma. Br J Surg 2017; 104 (13) 1775-1784 https://onlinelibrary.wiley.com/doi/pdf/10.1002/bjs.10677
47 Yin L, Li H, Li AJ. et al. Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan Criteria: a RCT. J Hepatol 2014; 61 (01) 82-88 https://www.sciencedirect.com/science/article/pii/S0168827814001561?via%3Dihub
48 Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30 (01) 52-60 https://www.thieme-connect.com/products/ejournals/pdf/10.1055/s-0030-1247132.pdf
49 Di Costanzo GG, Tortora R, DʼAdamo G. et al. Radiofrequency ablation versus laser ablation for the treatment of small hepatocellular carcinoma in cirrhosis: a randomized trial. J Gastroenterol Hepatol 2015; 30 (03) 559-565 https://onlinelibrary.wiley.com/doi/abs/10.1111/jgh.12791
50 Cucchetti A, Piscaglia F, Cescon M. et al. An explorative data-analysis to support the choice between hepatic resection and radiofrequency ablation in the treatment of hepatocellular carcinoma. Dig Liver Dis 2014; 46 (03) 257-263
51 Peng ZW, Zhang YJ, Chen MS. et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J Clin Oncol 2013; 31 (04) 426-432
52 Liu H, Wang ZG, Fu SY. et al. Randomized clinical trial of chemoembolization plus radiofrequency ablation versus partial hepatectomy for hepatocellular carcinoma within the Milan criteria. Br J Surg 2016; 103 (04) 348-356 https://bjssjournals.onlinelibrary.wiley.com/doi/full/10.1002/bjs.10061
53 Endo K, Kuroda H, Oikawa T. et al. Efficacy of combination therapy with transcatheter arterial chemoembolization and radiofrequency ablation for intermediate-stage hepatocellular carcinoma. Scand J Gastroenterol 2018; 53 (12) 1575-1583 https://www.tandfonline.com/doi/full/10.1080/00365521.2018.1548645
54 Lo CM, Ngan H, Tso WK. et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35 (05) 1164-1171 https://aasldpubs.onlinelibrary.wiley.com/doi/pdf/10.1053/jhep.2002.33156
55 Lammer J, Malagari K, Vogl T. et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010; 33 (01) 41-52 https://www.zora.uzh.ch/id/eprint/24207/1/Lammer_CardiovascInterventRadiol_2010_V.pdf
56 Golfieri R, Giampalma E, Renzulli M. et al. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer 2014; 111 (02) 255-264 https://iris.unito.it/retrieve/handle/2318/149077/25760/art%20Doxorubicina-Tace%202014.pdf
57 Abdel-Rahman O, Elsayed Z. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev 2020; 1 (01) Cd011313
58 Yang J, Wang J, Zhou H. et al. Efficacy and safety of endoscopic radiofrequency ablation for unresectable extrahepatic cholangiocarcinoma: a randomized trial. Endoscopy 2018; 50 (08) 751-760 https://www.thieme-connect.com/products/ejournals/pdf/10.1055/s-0043-124870.pdf
59 Ludwig JM, Zhang D, Xing M. et al. Meta-analysis: adjusted indirect comparison of drug-eluting bead transarterial chemoembolization versus (90)Y-radioembolization for hepatocellular carcinoma. Eur Radiol 2017; 27 (05) 2031-2041 https://link.springer.com/content/pdf/10.1007%2Fs00330-016-4548-3.pdf
60 Casadei GA, Tamburini E, Inarrairaegui M. et al. Radioembolization versus chemoembolization for unresectable hepatocellular carcinoma: a meta-analysis of randomized trials. Onco Targets Ther 2018; 11: 7315-7321 https://www.dovepress.com/getfile.php?fileID=45631
61 Mazzaferro V, Regalia E, Doci R. et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334 (11) 693-699 https://www.nejm.org/doi/pdf/10.1056/NEJM199603143341104?articleTools=true
62 Mazzaferro V, Llovet JM, Miceli R. et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009; 10 (01) 35-43 https://www.sciencedirect.com/science/article/pii/S1470204508702845?via%3Dihub
63 Yao FY, Ferrell L, Bass NM. et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33 (06) 1394-1403
64 Facciorusso A, Tartaglia N, Villani R. et al. Lenvatinib versus sorafenib as first-line therapy of advanced hepatocellular carcinoma: a systematic review and meta-analysis. Am J Transl Res 2021; 13 (04) 2379-2387 https://pubmed.ncbi.nlm.nih.gov/34017396/
65 Finn RS, Qin S, Ikeda M. et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med 2020; 382 (20) 1894-1905 https://www.nejm.org/doi/pdf/10.1056/NEJMoa1915745?articleTools=true
66 Cheng AL, Kang YK, Chen Z. et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10 (01) 25-34 https://www.sciencedirect.com/science/article/pii/S1470204508702857?via%3Dihub
67 Kudo M, Finn RS, Qin S. et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. The Lancet 2018; 391: 1163-1173
68 Bruix J, Qin S, Merle P. et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet 2017; 389: 56-66
69 Abou-Alfa GK, Meyer T, Cheng AL. et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med 2018; 379 (01) 54-63 https://www.nejm.org/doi/pdf/10.1056/NEJMoa1717002?articleTools=true
70 Zhu AX, Kang YK, Yen CJ. et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2019; 20 (02) 282-296
71 Llovet JM, Ricci S, Mazzaferro V. et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359 (04) 378-390 https://www.nejm.org/doi/pdf/10.1056/NEJMoa0708857?articleTools=true
72 Marrero JA, Kudo M, Venook AP. et al. Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study. J Hepatol 2016; 65 (06) 1140-1147 https://www.journal-of-hepatology.eu/article/S0168-8278(16)30346-4/pdf
73 Ganten TM, Stauber RE, Schott E. et al. Sorafenib in Patients with Hepatocellular Carcinoma-Results of the Observational INSIGHT Study. Clin Cancer Res 2017; 23 (19) 5720-5728 https://clincancerres.aacrjournals.org/content/clincanres/23/19/5720.full.pdf
74 Leal CRG, Magalhães C, Barbosa D. et al. Survival and tolerance to sorafenib in Child-Pugh B patients with hepatocellular carcinoma: a prospective study. Invest New Drugs 2018; 36 (05) 911-918 https://link.springer.com/article/10.1007/s10637-018-0621-x
75 Pressiani T, Boni C, Rimassa L. et al. Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis. Ann Oncol 2013; 24 (02) 406-411 https://www.annalsofoncology.org/article/S0923-7534(19)36863-2/pdf
76 Ogasawara S, Chiba T, Ooka Y. et al. Sorafenib treatment in Child-Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors. Invest New Drugs 2015; 33 (03) 729-739 https://link.springer.com/article/10.1007%2Fs10637-015-0237-3
77 Vilgrain V, Pereira H, Assenat E. et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol 2017; 18 (12) 1624-1636 https://www.sciencedirect.com/science/article/abs/pii/S1470204517306836
78 Chow PKH, Gandhi M, Tan SB. et al. SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma. J Clin Oncol 2018; 36 (19) 1913-1921 https://www.ncbi.nlm.nih.gov/pubmed/29498924
79 Lencioni R, Llovet JM, Han G. et al. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial. J Hepatol 2016; 64 (05) 1090-1098 https://www.ncbi.nlm.nih.gov/pubmed/26809111
80 Meyer T, Fox R, Ma YT. et al. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol 2017; 2 (08) 565-575 https://www.thelancet.com/pdfs/journals/langas/PIIS2468-1253(17)30156-5.pdf
81 Bruix J, Qin S, Merle P. et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017; 389: 56-66 https://www.sciencedirect.com/science/article/pii/S0140673616324539?via%3Dihub
82 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). Palliativmedizin für Patienten mit einer nicht-heilbaren Krebserkrankung. Version 2.2, 2020. https://www.leitlinienprogramm-onkologie.de/leitlinien/palliativmedizin/
83 Haun MW, Estel S, Rucker G. et al. Early palliative care for adults with advanced cancer. Cochrane Database Syst Rev 2017; 6: CD011129 http://www.ncbi.nlm.nih.gov/pubmed/28603881
84 Adler K, Schlieper D, Kindgen-Milles D. et al. [Integration of palliative care into intensive care: Systematic review]. Anaesthesist 2017; 66 (09) 660-666 http://www.ncbi.nlm.nih.gov/pubmed/28589374
85 Dalgaard KM, Bergenholtz H, Nielsen ME. et al. Early integration of palliative care in hospitals: A systematic review on methods, barriers, and outcome. Palliat Support Care 2014; 12 (06) 495-513 http://www.ncbi.nlm.nih.gov/pubmed/24621947
86 Davis MP, Temel JS, Balboni T. et al. A review of the trials which examine early integration of outpatient and home palliative care for patients with serious illnesses. Ann Palliat Med 2015; 4 (03) 99-121 http://www.ncbi.nlm.nih.gov/pubmed/26231807
87 Hui D, Kim YJ, Park JC. et al. Integration of oncology and palliative care: a systematic review. Oncologist 2015; 20 (01) 77-83 http://www.ncbi.nlm.nih.gov/pubmed/25480826
88 Hui D, Meng YC, Bruera S. et al. Referral Criteria for Outpatient Palliative Cancer Care: A Systematic Review. Oncologist 2016; 21 (07) 895-901 http://www.ncbi.nlm.nih.gov/pubmed/27185614
89 Tassinari D, Drudi F, Monterubbianesi MC. et al. Early Palliative Care in Advanced Oncologic and Non-Oncologic Chronic Diseases: A Systematic Review of Literature. Rev Recent Clin Trials 2016; 11 (01) 63-71 http://www.ncbi.nlm.nih.gov/pubmed/26464077
90 Gärtner U, Braun GD, Held K. et al. [Physical complaints, stress and quality of life of oncologic patients. Effects and patient assessment in inpatient rehabilitation]. Med Klin (Munich) 1996; 91 (08) 501-508
91 Atchison EA, Gridley G, Carreon JD. et al. Risk of cancer in a large cohort of U.S. veterans with diabetes. Int J Cancer 2011; 128 (03) 635-643 https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ijc.25362?download=true
92 de Valle MB, Björnsson E, Lindkvist B. Mortality and cancer risk related to primary sclerosing cholangitis in a Swedish population-based cohort. Liver Int 2012; 32 (03) 441-448 https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1478-3231.2011.02614.x?download=true
93 El-Serag HB, Engels EA, Landgren O. et al. Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population-based study of U. S. veterans. Hepatology 2009; 49 (01) 116-123 https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hep.22606?download=true
94 Huang Y, You L, Xie W. et al. Smoking and risk of cholangiocarcinoma: a systematic review and meta-analysis. Oncotarget 2017; 8 (59) 100570-100581 https://www.oncotarget.com/article/20141/pdf/
95 Jing W, Jin G, Zhou X. et al. Diabetes mellitus and increased risk of cholangiocarcinoma: a meta-analysis. Eur J Cancer Prev 2012; 21 (01) 24-31
96 Palmer WC, Patel T. Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. J Hepatol 2012; 57 (01) 69-76 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3804834/pdf/nihms363811.pdf
97 Wongjarupong N, Assavapongpaiboon B, Susantitaphong P. et al. Non-alcoholic fatty liver disease as a risk factor for cholangiocarcinoma: a systematic review and meta-analysis. BMC Gastroenterol 2017; 17 (01) 149 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5721586/pdf/12876_2017_Article_696.pdf
98 Park JY, Hong SP, Kim YJ. et al. Long-term follow up of gallbladder polyps. J Gastroenterol Hepatol 2009; 24 (02) 219-222 https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1440-1746.2008.05689.x?download=true
99 Nagaraja V, Eslick GD. Systematic review with meta-analysis: the relationship between chronic Salmonella typhi carrier status and gall-bladder cancer. Aliment Pharmacol Ther 2014; 39 (08) 745-750 https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/apt.12655?download=true
100 Zhang H, Zhu J, Ke F. et al. Radiological Imaging for Assessing the Respectability of Hilar Cholangiocarcinoma: A Systematic Review and Meta-Analysis. Biomed Res Int 2015; 2015: 497942 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4569758/pdf/BMRI2015-497942.pdf
101 De Moura DTH, Moura EGH, Bernardo WM. et al. Endoscopic retrograde cholangiopancreatography versus endoscopic ultrasound for tissue diagnosis of malignant biliary stricture: Systematic review and meta-analysis. Endosc Ultrasound 2018; 7 (01) 10-19 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5838722/pdf/EUS-7-10.pdf
102 Navaneethan U, Hasan MK, Lourdusamy V. et al. Single-operator cholangioscopy and targeted biopsies in the diagnosis of indeterminate biliary strictures: a systematic review. Gastrointest Endosc 2015; 82 (04) 608-614.e2 https://www.ncbi.nlm.nih.gov/pubmed/26071061
103 Becker NS, Rodriguez JA, Barshes NR. et al. Outcomes analysis for 280 patients with cholangiocarcinoma treated with liver transplantation over an 18-year period. J Gastrointest Surg 2008; 12 (01) 117-122 https://link.springer.com/content/pdf/10.1007/s11605-007-0335-4.pdf
104 Darwish MuradS, Kim WR, Harnois DM. et al. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology 2012; 143 (01) 88-98.e3 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3846443/pdf/nihms507180.pdf
105 Mosconi C, Solaini L, Vara G. et al. Transarterial Chemoembolization and Radioembolization for Unresectable Intrahepatic Cholangiocarcinoma-a Systemic Review and Meta-Analysis. Cardiovasc Intervent Radiol 2021; 44 (05) 728-738 https://pubmed.ncbi.nlm.nih.gov/33709272/
106 Zhen Y, Liu B, Chang Z. et al. A pooled analysis of transarterial radioembolization with yttrium-90 microspheres for the treatment of unresectable intrahepatic cholangiocarcinoma. Onco Targets Ther 2019; 12: 4489-4498 https://pubmed.ncbi.nlm.nih.gov/31239717/
107 Primrose JN, Fox RP, Palmer DH. et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol 2019; 20 (05) 663-673 https://www.sciencedirect.com/science/article/abs/pii/S147020451830915X?via%3Dihub
108 Markussen A, Jensen LH, Diness LV. et al. Treatment of Patients with Advanced Biliary Tract Cancer with Either Oxaliplatin, Gemcitabine, and Capecitabine or Cisplatin and Gemcitabine-A Randomized Phase II Trial. Cancers (Basel) 2020; 12 (07) 1975 https://pubmed.ncbi.nlm.nih.gov/32698410/
109 Valle J, Wasan H, Palmer DH. et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362 (14) 1273-1281 https://www.nejm.org/doi/pdf/10.1056/NEJMoa0908721?articleTools=true
110 Okusaka T, Nakachi K, Fukutomi A. et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer 2010; 103 (04) 469-474 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2939781/pdf/6605779a.pdf
111 Valle JW, Furuse J, Jitlal M. et al. Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials. Ann Oncol 2014; 25 (02) 391-398
112 Park JO, Oh DY, Hsu C. et al. Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review. Cancer Res Treat 2015; 47 (03) 343-361 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4509359/pdf/crt-2014-308.pdf
113 Abou-Alfa GK, Sahai V, Hollebecque A. et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol 2020; 21 (05) 671-684 https://pubmed.ncbi.nlm.nih.gov/32203698/
114 Lamarca A, Palmer DH, Wasan HS. et al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol 2021; 22 (05) 690-701 https://pubmed.ncbi.nlm.nih.gov/33798493/